New obesity drug target demands dual approach to work, study finds

Blocking a single protein isn't enough to fight obesity—researchers found that inhibiting all versions of a protein called SHIP only works when immune cells called eosinophils are functioning normally. The finding could reshape how drugmakers design obesity treatments and screen candidates for efficacy before costly clinical trials.

Originaltitel: Obesity control by SHIP inhibition requires pan-paralog inhibition and an intact eosinophil compartment